Stocks’ Details
 

NoxoPharm Ltd

Completed the transfer of shares to Nyrada: NoxoPharm Ltd (ASX: NOX) has completed the transfer of shares underlying the establishment of US subsidiary, Nyrada Inc. NOX had formed Nyrada as a US subsidiary company as a non-oncology drug development business that now owns the intellectual property rights in three non-oncology drug programs after the transfer of shares. On the other hand, NOX has released interim data from its first-in-human study of NOX66 that was conducted in Georgia and the data entailed encouraging outcomes on safety and disease control in patients receiving NOX66 along with a low dose of carboplatin. With the release of the data and other presentations that the group has been delivering to gain traction, NOX stock surged up 93.18% in one month as on November 20, 2017. Given the run-up while it would be better to wait for more positives, we put an “Expensive” recommendation on the stock at the current price of $0.83
 

Nanosonics Ltd

Growth in FY 17 and global expansion: Nanosonics Ltd (ASX: NAN) in FY 17 has reported 58% growth in sales to $67.58 million, and posted a significant pre-tax profit of $13.9 million compared with $136,000 in the prior year while free cash flow of $15.1 million was up from $1.9 million in FY 16. Moreover, in FY 17, NAN’s flagship trophon product has witnessed an increased global installed base of 41% to more than 14,100 units, each generating the opportunity for significant annuity revenue. NAN has continued global market expansion, established its direct sales operations in Canada and signed the agreement with Sakura Seiki for the distribution of the trophon system in the important Japanese market. Additionally, NAN has planned geographic expansion across Europe, Middle East and Asia Pacific to broaden its global footprint. Based on above efforts, NAN expects the operational expense for the FY 18 to be approximately $48 million, which includes $14 million in R&D. Meanwhile, NAN stock has risen 19.92% in three months as on November 20, 2017. Based on slightly higher levels of trading, we give a “Hold” recommendation on the stock at the current price of $2.77


North America Installed base (Source: Company Reports)
 

Mayne Pharma Group Ltd

Launched the full range of clozapine tablets in US:Mayne Pharma Group Ltd (ASX: MYX) has launched the full range of clozapine tablets (25mg, 50mg, 100mg and 200mg) in the United States. This product is currently manufactured by Teva Pharmaceuticals Industries Limited and will now be manufactured at the facility in Greenville, North Carolina. The new solid oral dose manufacturing facility is planned to open in early 2018 and will quadruple MYX’s U.S. manufacturing capacity to well over 1 billion doses, and importantly introduces significant new capacity to manufacture high potent compounds and new capability to manufacture modified-release bead/pellet products. Meanwhile, MYX stock has fallen 16.55% in three months as on November 20, 2017, owing to weakness in the generic drugs market. Further, there is a consolidation of wholesalers in the United States, which led to significant pricing pressures. Based on the foregoing, we give an “Expensive” recommendation on the stock at the current price of $0.615
 

Fisher & Paykel Healthcare Corp Ltd

Financial Performance: Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) in the first half-year ending September 30, 2017 has reported for 4% growth in the net profit after tax to NZ$81.3 million over the prior comparable period. Operating revenue grew 8% to NZ$458.4 million compared to the first half last year. FPH has also declared an interim dividend of 8.75 NZ cents per ordinary share, which is an increase of 6% on the interim dividend last year. The interim dividend, carrying full New Zealand imputation credit, will be paid in December 2017. Moreover, for FY 18, FPH expects the operating revenue to be approximately NZ$1 billion and net profit after tax to be approximately between NZ$185 to NZ$190 million. However, the stock lost over 3.8% on November 21, 2017 with investors disappointed with costs relating to legal fights with ResMed and concerns over any regulatory or macro level changes with regards to capability to manufacture in Mexico. Based on the foregoing, we give an “Expensive” recommendation on the stock at the current price of $11.90
 

Financial Performance (Source: Company Reports)

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.